V. Kronsten, M. Colwill, S. Nayeemuddin, J. Limdi, C. Selinger, G. Scott, L. Al‐Hillawi, S. Salehi, P. Blaker, G. Chung-Faye, A. Kent, P. Dubois, B. Hayee
{"title":"一项“真实世界”回顾性多中心队列研究比较英夫利昔单抗和阿达木单抗维持溃疡性结肠炎缓解的疗效","authors":"V. Kronsten, M. Colwill, S. Nayeemuddin, J. Limdi, C. Selinger, G. Scott, L. Al‐Hillawi, S. Salehi, P. Blaker, G. Chung-Faye, A. Kent, P. Dubois, B. Hayee","doi":"10.1002/ygh2.467","DOIUrl":null,"url":null,"abstract":"Anti‐tumour necrosis factor therapy is an established treatment for moderate‐to‐severely active ulcerative colitis (UC). Recent network meta‐analyses of controlled trial data have indicated a superiority of intravenous drugs (infliximab) over subcutaneous (adalimumab). We conducted a retrospective multi‐centre cohort study to determine the comparative effectiveness of these two drugs.","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"45 1","pages":"229 - 235"},"PeriodicalIF":0.0000,"publicationDate":"2021-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"A ‘real‐world’ retrospective multi‐centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis\",\"authors\":\"V. Kronsten, M. Colwill, S. Nayeemuddin, J. Limdi, C. Selinger, G. Scott, L. Al‐Hillawi, S. Salehi, P. Blaker, G. Chung-Faye, A. Kent, P. Dubois, B. Hayee\",\"doi\":\"10.1002/ygh2.467\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Anti‐tumour necrosis factor therapy is an established treatment for moderate‐to‐severely active ulcerative colitis (UC). Recent network meta‐analyses of controlled trial data have indicated a superiority of intravenous drugs (infliximab) over subcutaneous (adalimumab). We conducted a retrospective multi‐centre cohort study to determine the comparative effectiveness of these two drugs.\",\"PeriodicalId\":12480,\"journal\":{\"name\":\"GastroHep\",\"volume\":\"45 1\",\"pages\":\"229 - 235\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"GastroHep\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/ygh2.467\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"GastroHep","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/ygh2.467","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A ‘real‐world’ retrospective multi‐centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis
Anti‐tumour necrosis factor therapy is an established treatment for moderate‐to‐severely active ulcerative colitis (UC). Recent network meta‐analyses of controlled trial data have indicated a superiority of intravenous drugs (infliximab) over subcutaneous (adalimumab). We conducted a retrospective multi‐centre cohort study to determine the comparative effectiveness of these two drugs.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
